Luigi Formisano, Associate Professor of Medical Oncology at University of Naples Federico II, shared a post on LinkedIn:
“What a meeting! It was truly an honour to take part in this incredible event on radioligand therapy in prostate cancer. Lutetium-177 PSMA is finally here — and it’s opening new horizons for our patients and clinical practice.”
